Movement Alert｜AstraZeneca Falls 3.03% in Regular Trading, Phase III Trial Misses Primary Endpoint Amid Broad Pharma Sector Weakness

Market Focus06-01

On June 1, AstraZeneca fell 3.03% in regular trading, trading at approximately $179.98/share, with trading volume of approximately $89.95 million.

On the news front, AstraZeneca's Alexion Rare Disease unit disclosed that its CARES Phase III clinical program evaluating anselamimab in light chain amyloidosis did not meet its primary endpoint in the overall patient population. While the pre-specified Kappa subgroup showed a 62% improvement in all-cause mortality and a 71% reduction in cardiovascular hospitalization rates, the overall data failed to reach statistical significance, representing a pipeline-level headwind.

Adding to company-specific pressure, the broader pharmaceutical sector experienced a synchronized selloff. Within the Pharmacy sector, Eli Lilly fell 2.2%, Johnson & Johnson declined 1.72%, Pfizer dropped 2.59%, Merck lost 3.15%, and Bristol-Myers Squibb slid 3.83%, amplifying downward momentum through sector-wide linkage effects.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122137217?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122137217","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AstraZeneca Falls 3.03% in Regular Trading, Phase III Trial Misses Primary Endpoint Amid Broad Pharma Sector Weakness","media":"Market Focus","content":"<p><p>On June 1, AstraZeneca fell 3.03% in regular trading, trading at approximately $179.98/share, with trading volume of approximately $89.95 million.</p><p>On the news front, AstraZeneca's Alexion Rare Disease unit disclosed that its CARES Phase III clinical program evaluating anselamimab in light chain amyloidosis did not meet its primary endpoint in the overall patient population. While the pre-specified Kappa subgroup showed a 62% improvement in all-cause mortality and a 71% reduction in cardiovascular hospitalization rates, the overall data failed to reach statistical significance, representing a pipeline-level headwind.</p><p>Adding to company-specific pressure, the broader pharmaceutical sector experienced a synchronized selloff. Within the Pharmacy sector, Eli Lilly fell 2.2%, Johnson & Johnson declined 1.72%, Pfizer dropped 2.59%, Merck lost 3.15%, and Bristol-Myers Squibb slid 3.83%, amplifying downward momentum through sector-wide linkage effects.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AstraZeneca Falls 3.03% in Regular Trading, Phase III Trial Misses Primary Endpoint Amid Broad Pharma Sector Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AstraZeneca Falls 3.03% in Regular Trading, Phase III Trial Misses Primary Endpoint Amid Broad Pharma Sector Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-01 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 1, AstraZeneca fell 3.03% in regular trading, trading at approximately $179.98/share, with trading volume of approximately $89.95 million.</p><p>On the news front, AstraZeneca's Alexion Rare Disease unit disclosed that its CARES Phase III clinical program evaluating anselamimab in light chain amyloidosis did not meet its primary endpoint in the overall patient population. While the pre-specified Kappa subgroup showed a 62% improvement in all-cause mortality and a 71% reduction in cardiovascular hospitalization rates, the overall data failed to reach statistical significance, representing a pipeline-level headwind.</p><p>Adding to company-specific pressure, the broader pharmaceutical sector experienced a synchronized selloff. Within the Pharmacy sector, Eli Lilly fell 2.2%, Johnson & Johnson declined 1.72%, Pfizer dropped 2.59%, Merck lost 3.15%, and Bristol-Myers Squibb slid 3.83%, amplifying downward momentum through sector-wide linkage effects.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"","article_id":"1122137217","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122137217","pubTimestamp":1780325633,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 1, AstraZeneca fell 3.03% in regular trading, trading at approximately $179.98/share, with trading volume of approximately $89.95 million.On the news front, AstraZeneca's Alexion Rare Disease...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"动向提示|阿斯利康常规交易下跌3.03%，制药行业普遍疲软，III期试验未达主要终点","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"On June 1, AstraZeneca fell 3.03% in regular trading, trading at approximately $179.98/share, with trading volume of approximately $89.95 million.On the news front, AstraZeneca's Alexion Rare Disease unit disclosed that its CARES Phase III clinical program evaluating anselamimab in light chain amyloidosis did not meet its primary endpoint in the overall patient population. While the pre-specified Kappa subgroup showed a 62% improvement in all-cause mortality and a 71% reduction in cardiovascular hospitalization rates, the overall data failed to reach statistical significance, representing a pipeline-level headwind.Adding to company-specific pressure, the broader pharmaceutical sector experienced a synchronized selloff. Within the Pharmacy sector, Eli Lilly fell 2.2%, Johnson & Johnson declined 1.72%, Pfizer dropped 2.59%, Merck lost 3.15%, and Bristol-Myers Squibb slid 3.83%, amplifying downward momentum through sector-wide linkage effects.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122137217","isCrawlerRequest":true}